Click on headlines below to download research

FY21e EBITDA ‘materially ahead’ of consensus
Ergomed | 11/06/2021

Yesterday, Ergomed held its annual general meeting (AGM) and provided a high-level year to date trading update (four months to end-April 2021). The company…

What’s next after stellar 2020 performance?
Ergomed | 01/06/2021

Although most of 2020 was challenging for the contract research outsourcing (CRO) sector, for Ergomed it was a transformative growth period due to well-balanced…

Transformative 2020; solid fundamentals for 2021
Ergomed | 23/03/2021

Ergomed’s FY20 results released today showed that adjusted EBITDA of £19.4m was 4.2% ahead of our estimate. This was a positive surprise after…